

Edgar Filing: Stem Cell Therapy International, Inc. - Form NT 10-K

Stem Cell Therapy International, Inc.  
Form NT 10-K  
June 29, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12B-25

NOTIFICATION OF LATE FILING

Commission File Number 0-51931

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  
 Form 10-D  Form N-SAR  Form N-CSR  
FOR PERIOD ENDED: March 31, 2007  
-----

Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q  
 Transition Report on Form N-SAR  
FOR THE TRANSITION PERIOD ENDED:

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.  
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS  
VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify  
the item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Stem Cell Therapy International, Inc  
-----

Full Name of Registrant

-----  
Former Name if Applicable

2203 N. Lois Avenue, 9th Floor  
-----

Address of Principal Executive Offices (Street and Number)

Tampa, FL 33607  
-----

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense  
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following  
should be completed. (Check appropriate box)

| (a) The reasons described in reasonable detail in Part III of this form

Edgar Filing: Stem Cell Therapy International, Inc. - Form NT 10-K

| could not be eliminated without unreasonable effort or expense;

| -----  
| (b) The subject annual report, semi-annual report, transition report on  
| Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof  
| will be filed on or before the 15th calendar day following the prescribed  
[x]| due date; or the subject quarterly report or transition report on Form 10-  
| Q, 10-QSB, or portion thereof will be filed on or before the fifth  
calendar day following the prescribed due date; and

| (c) The accountant's statement or other exhibit required by Rule 12b-  
25(c) has been attached if applicable.

1

PART III  
NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 10-KSB, 11-K, 20-F, 10-Q, 10-QSB, N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The registrant has experienced delays in completing its financial statements for the year ended March 31, 2007 as the registrant's auditor has not had sufficient time to conduct a review. As a result, the registrant is delayed in filing its Form 10-K for the year ended March 31, 2007

PART IV

OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

M. Richard Cutler	706	737-6600
-----	-----	-----
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). [X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

STEM CELL THERAPY INTERNATIONAL, INC.

-----  
(Name of Registrant as specified in charter)

Edgar Filing: Stem Cell Therapy International, Inc. - Form NT 10-K

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date June 29, 2007  
-----

By: /s/ Calvin Cao  
-----  
Calvin Cao, Chief Executive Officer